These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15896465)

  • 21. PTEN represses RNA Polymerase I transcription by disrupting the SL1 complex.
    Zhang C; Comai L; Johnson DL
    Mol Cell Biol; 2005 Aug; 25(16):6899-911. PubMed ID: 16055704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of sensitivity to TRAIL by the PTEN tumor suppressor.
    Whang YE; Yuan XJ; Liu Y; Majumder S; Lewis TD
    Vitam Horm; 2004; 67():409-26. PubMed ID: 15110188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding.
    Adey NB; Huang L; Ormonde PA; Baumgard ML; Pero R; Byreddy DV; Tavtigian SV; Bartel PL
    Cancer Res; 2000 Jan; 60(1):35-7. PubMed ID: 10646847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of synovial fibroblasts in rheumatoid arthritis: lack of Expression of the tumour suppressor PTEN at sites of invasive growth and destruction.
    Pap T; Franz JK; Hummel KM; Jeisy E; Gay R; Gay S
    Arthritis Res; 2000; 2(1):59-64. PubMed ID: 11219390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Membrane-binding and activation mechanism of PTEN.
    Das S; Dixon JE; Cho W
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7491-6. PubMed ID: 12808147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.
    Zheng HC; Li YL; Sun JM; Yang XF; Li XH; Jiang WG; Zhang YC; Xin Y
    World J Gastroenterol; 2003 Aug; 9(8):1662-6. PubMed ID: 12918097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.
    Weng LP; Smith WM; Dahia PL; Ziebold U; Gil E; Lees JA; Eng C
    Cancer Res; 1999 Nov; 59(22):5808-14. PubMed ID: 10582703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein.
    Okahara F; Ikawa H; Kanaho Y; Maehama T
    J Biol Chem; 2004 Oct; 279(44):45300-3. PubMed ID: 15355975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene.
    Tolkacheva T; Chan AM
    Oncogene; 2000 Feb; 19(5):680-9. PubMed ID: 10698513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor.
    Okumura K; Zhao M; Depinho RA; Furnari FB; Cavenee WK
    Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2703-6. PubMed ID: 15659546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The human tumour suppressor PTEN regulates longevity and dauer formation in Caenorhabditis elegans.
    Solari F; Bourbon-Piffaut A; Masse I; Payrastre B; Chan AM; Billaud M
    Oncogene; 2005 Jan; 24(1):20-7. PubMed ID: 15637588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.
    Lee JO; Yang H; Georgescu MM; Di Cristofano A; Maehama T; Shi Y; Dixon JE; Pandolfi P; Pavletich NP
    Cell; 1999 Oct; 99(3):323-34. PubMed ID: 10555148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PTEN and myotubularin: novel phosphoinositide phosphatases.
    Maehama T; Taylor GS; Dixon JE
    Annu Rev Biochem; 2001; 70():247-79. PubMed ID: 11395408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PTEN function: how normal cells control it and tumour cells lose it.
    Leslie NR; Downes CP
    Biochem J; 2004 Aug; 382(Pt 1):1-11. PubMed ID: 15193142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biology and clinical relevance of the PTEN tumor suppressor pathway.
    Sansal I; Sellers WR
    J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.
    Walker SM; Leslie NR; Perera NM; Batty IH; Downes CP
    Biochem J; 2004 Apr; 379(Pt 2):301-7. PubMed ID: 14711368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
    Nielsen-Preiss SM; Silva SR; Gillette JM
    J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells.
    Yi HK; Kim SY; Hwang PH; Kim CY; Yang DH; Oh Y; Lee DY
    Biochem Biophys Res Commun; 2005 May; 330(3):760-7. PubMed ID: 15809062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity.
    Gildea JJ; Herlevsen M; Harding MA; Gulding KM; Moskaluk CA; Frierson HF; Theodorescu D
    Oncogene; 2004 Sep; 23(40):6788-97. PubMed ID: 15273733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.